- Home
- RAND vs FGEN Comparison
RAND vs FGEN Comparison
Compare RAND & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAND
- FGEN
- Stock Information
- Founded
- RAND 1969
- FGEN 1993
- Country
- RAND United States
- FGEN United States
- Employees
- RAND N/A
- FGEN N/A
- Industry
- RAND Finance: Consumer Services
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- RAND Finance
- FGEN Health Care
- Exchange
- RAND Nasdaq
- FGEN Nasdaq
- Market Cap
- RAND 41.3M
- FGEN 45.1M
- IPO Year
- RAND N/A
- FGEN 2014
- Fundamental
- Price
- RAND $14.00
- FGEN $8.66
- Analyst Decision
- RAND
- FGEN Strong Buy
- Analyst Count
- RAND 0
- FGEN 2
- Target Price
- RAND N/A
- FGEN $146.50
- AVG Volume (30 Days)
- RAND 3.0K
- FGEN 32.4K
- Earning Date
- RAND 11-07-2025
- FGEN 11-10-2025
- Dividend Yield
- RAND 11.94%
- FGEN N/A
- EPS Growth
- RAND N/A
- FGEN N/A
- EPS
- RAND N/A
- FGEN 53.38
- Revenue
- RAND $7,327,287.00
- FGEN $8,298,000.00
- Revenue This Year
- RAND N/A
- FGEN N/A
- Revenue Next Year
- RAND N/A
- FGEN N/A
- P/E Ratio
- RAND N/A
- FGEN $0.16
- Revenue Growth
- RAND N/A
- FGEN N/A
- 52 Week Low
- RAND $13.40
- FGEN $4.85
- 52 Week High
- RAND $31.89
- FGEN $21.94
- Technical
- Relative Strength Index (RSI)
- RAND 50.04
- FGEN 25.01
- Support Level
- RAND $13.76
- FGEN $8.50
- Resistance Level
- RAND $14.00
- FGEN $11.39
- Average True Range (ATR)
- RAND 0.23
- FGEN 0.50
- MACD
- RAND 0.06
- FGEN -0.25
- Stochastic Oscillator
- RAND 100.00
- FGEN 12.62
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.